32 results about "Pharmacokinetic analysis" patented technology

A method for pharmacokinetic analysis, including: receiving time-series medical image data of a patient introduced with a contrast agent; identifying a reference region in the medical image data; identifying a plurality of points of interest in the medical image data; measuring an intensity of voxels in the reference region; and for each point of interest, measure an intensity of voxels therein, use the measured reference region and point of interest intensities to obtain an expression relating the point of interest's voxel concentration to that of the reference region, wherein the expression is a five-parameter nonlinear model with no reference to an arterial input function; and obtain values for each of the five-parameters by solving the expression and use the obtained values to determine whether the point of interest is malignant.

The invention provides an analytical method for pharmacokinetics of a multicomponent traditional Chinese medicine, and belongs to the technical field of medicine component analysis. Quantitative reactive ions of various components in bulk pharmaceutical chemicals are built in a multiple reaction monitor scanning manner of liquid chromatogram-tandem mass spectrometry and taking the bulk pharmaceutical chemicals as 'standard substances', and the concentrations of various traditional Chinese medicine components in a biological sample are relatively quantified. The method comprises the following specific steps: preparing a bulk pharmaceutical chemical solution; building a liquid chromatogram-mass spectrometry analysis condition; testing in vivo; measuring the biological sample; and processing the data. The method provided by the invention ensures that the quantitative analysis on multicomponent traditional Chinese medicine in the biological sample is realized without the standard substance. By utilizing the method, the pharmacokinetic analysis is performed on the known or unknown components in a traditional Chinese preparation. The result shows that the precision and accuracy obtained by the method conform to the requirements of relevant specifications of SFDA (the State Food and Drug Administration).

The invention discloses a detection method of ticagrelor in human plasma and active metabolite concentration thereof. The method comprises the following steps: (1) preparing a standard working solution; (2) treating a sample; (3) manufacturing a standard curve; (4) quantitatively analyzing: treating a test sample according to the method of step (2), and computing according to a standard curve equation obtained in the step (3) to obtain the ticagrelor in the human plasma and the concentration of the active metabolite concentration thereof. The ticagrelor in the human plasma and the concentration of the active metabolite concentration thereof are determined by applying the high-performance liquid chromatography (HPLC), the ticagrelor in the human plasma and the concentration of the active metabolite concentration thereof can be accurately quantified; through the reasonable selection of a chromatographic column, a pre-treatment method, mobile phase and a mass spectrum condition and the optimization of the flow velocity, the mobile phase proportion, the chromatographic condition and like experimental conditions, the series of methodology verifies that the whole quantitative detection method is practicable, simple and convenient for operation, good in repeatability, good in accuracy, and strong in operability, and can be directly applied to the plasma sample detection analysis of the clinical patient and the related pharmacokinetics analysis.

Disclosed are methods and kits for pharmacokinetic profiling employing point-of-care or point of service self-sampling and allowing for dosage adjustments based on the pharmacokinetic profiles.

The invention relates to a small RNA detection method and a use thereof and belongs to the field of double-stranded small RNA detection. The small RNA detection method comprises the following steps of 1, designing multiple continuous or discontinuous closed RNAs which are complementary with one chain of a small RNA, a reverse transcription stem-loop primer which is complementary with an end 3' of the other chain of the small RNA, and a forward primer and a reverse primer for quantitative PCR, and 2, detecting the small RNA by denaturation, enclosing, inverse transcription and quantitative PCR. The small RNA detection method has simple processes, a low detection cost, a detection limit reaching a femtogram grade, high detection efficiency, strong singularity and high sensitivity. The small RNA detection method can be widely used for quantitative analysis, qualitative analysis and pharmacokinetic analysis of a small RNA drug, for amplification, specific identification and differentiation of a small RNA molecule, and especially for molecular diagnosis, small RNA drug metabolism and small RNA drug functional study.

The method for constructing the motion sickness model of Long Hu Ren Dan comprises the following steps: (1) animal preparation: clean rats; (2) establishment of motion sickness model; (3) administration and sample collection; (4) Sample determination and (5) pharmacokinetic analysis and statistical analysis, calculate the plasma drug concentration of the active ingredient in the corresponding batch through the accompanying standard curve of each determination batch, and obtain the concentration-time data. In this study, the 8 non-volatile components LC-MS/MS and 4 volatile components HS-SPDE-GC-MS/MS biological sample analysis methods in Longhu Rendan were used to study the normal and Pharmacokinetic study rules in rats with motion sickness. The results of the present invention can provide help for understanding the anti-motion sickness medicinal substance of Longhuren Dan.

The invention discloses a method for quantitatively analyzing the modification level of a covalent drug and a metabolite of the covalent drug on protein from the amino acid level, and is applied to the research of pharmacokinetics. The method comprises the following steps: (1) adding a covalent drug and a capture reagent into an in-vitro incubation system for incubation, taking incubation liquid for analysis, identifying an adduct formed by the covalent drug and a metabolite thereof and the capture reagent, and determining a metabolite structure with covalent modification capacity and modified target amino acid; (2) preparing a standard substance of the adduct in the step (1), detecting chromatographic and mass spectrometric data of the standard substance through UHPLC-QQQ-MS, and establishing a quantitative analysis method; and (3) carrying out enzymolysis on a biological drug delivery sample of the covalent drug, detecting the obtained enzymolysis product by adopting UHPLC-QQQ-MS, and determining the content of the adduct in the biological drug delivery sample according to the detection result in combination with the chromatographic and mass spectrometric data in the step (2).

The invention provides a detection antibody of an anti-VEGFR-2 monoclonal antibody, application and a detection method. The detection antibody comprises a heavy chain variable region and a light chainvariable region, and the amino acid sequence of the heavy chain variable region is selected from SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8; and the amino acid sequence of the light chain variable region is selected from SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12. According to the detection antibody, the detection antibody aiming at the anti-VEGFR-2 monoclonal antibody is obtained by screening, the antibody can be used for rapidly, sensitively and accurately detecting the drug concentration of the anti-VEGFR-2 monoclonal antibody in body fluid, and a reliable research method is provided for assisting the clinical diagnosis of the anti-VEGFR-2 monoclonal antibody and the pharmacological and pharmacokinetic analysis of a clinical test.

The invention discloses a method for detecting living cells by fluorescent negative staining. Fluorescent staining reagents stain whole cells, and when cells phagocytize opaque nano-particles, the nano-particles are enriched in the phagocytic body. Cut off the detection light so that it appears as a fluorescent negative staining area on the fluorescence image. According to the size of the negative staining area, the phagocytosis rate of the cells to the nanoparticles can be easily judged without affecting the activity of the cells. The CFSE fluorescence negative staining method of the cell labeling detection method of the present invention can be used for the detection of labeling rate and labeling amount after nano-iron-labeled cells, and for evaluating the pharmacodynamics and pharmacokinetics analysis of nano-iron-type new drugs, and the method Cells do not need to be fixed, CFSE staining is simple and convenient, and maintains the viability of cells.

The invention relates to the field of pharmacokinetic analysis, in particular to an HPLC (High Performance Liquid Chromatography) method for determining the content of curcumin and paclitaxel in a biological sample. The method comprises a standard curve establishment step and a sample detection step in sequence. The HPLC analysis method is characterized in that a Luna@5[mu]m C18 (4.6mmx250mm) chromatographic analysis column and a gradient elution variable-wavelength method are adopted. Through adoption of the method, simultaneous determination of the content of curcumin and paclitaxel in the biological sample is realized by only HPLC; the efficiency of pharmacokinetic study of curcumin and paclitaxel combination is improved rapidly; the development process of curcumin and paclitaxel combination can be promoted rapidly; and the time, manpower and economic cost is greatly lowered for research and development enterprises and scientific research institutions.

System that automates analysis of mass spectrometry data for oligonucleotides to generate pharmacokinetic parameters and models. A user inputs an oligonucleotide sequence and a maximum number of nucleotides that may be lost during metabolism while retaining therapeutic effectiveness. The system calculates the possible active metabolites and develops a mass spectrum filter for the mass-to-charge ratio of ions for these metabolites. Full-scan spectra are analyzed to calculate the total concentration of these active molecules present in a time series of samples. Pharmacokinetic models and parameters are calculated from the time series of total concentration. Because full-scan spectra are captured, assumptions may be modified and analyses may be quickly rerun without collecting additional data. Overall pharmacokinetic analysis is therefore much more streamlined and efficient, reducing cost, delay, and the need for a mass spectrometrist who is highly skilled in spectral analysis.

A pharmacokinetic analysis method for monitoring therapeutic drugs comprises the following steps: (1) establishing a plasma concentration determination method: establishing the plasma concentration determination method capable of simultaneously monitoring the therapeutic drugs and main metabolites thereof in a plasma sample of a patient by adopting UPLC-MS/MS, and performing methodological verification on the established plasma concentration determination method; (2) establishing a pharmacokinetic model; and (3) monitoring treatment drugs. The pharmacokinetic analysis method for monitoring the therapeutic drug is reasonable in design, provides a basis for individualization of clinical medication of the therapeutic drug by taking the therapeutic drug as a monitoring target, taking blood concentration monitoring as a core and combining pharmacokinetic research data, and provides a basis for clinical medication individualization of the therapeutic drug by monitoring the therapeutic drug for a patient. The curative effect of the treatment medicine can be obviously improved, the occurrence risk of adverse reaction of the treatment medicine is reduced, and the application prospect is wide.

The invention provides a magnetic resonance contrast agent based on hyaluronic acid as well as a preparation method and application thereof, and belongs to the technical field of medical imaging. The magnetic resonance contrast agent is a hyaluronic acid-based polymer, and the structure of the polymer is shown as a formula (I). The relaxation rate of the liver fibrosis specific MRI imaging contrast agent HTCDGd is three times that of clinical small molecule DTPA-Gd. Pharmacokinetic analysis, MRI and fluorescence imaging confirm that HTCDGd circulates in vivo for a long time and accumulates effectively in the liver. For the diagnosis of hepatic fibrosis, HTCDGd shows excellent fibrosis tissue targeting ability, through MRI enhancement, not only are differences of different degrees of hepatic fibrosis tissue enhancement degrees and longer imaging window observation periods provided, but also morphological characteristics of different degrees of hepatic fibrosis can be directly displayed, and early diagnosis and accurate staging of hepatic fibrosis are realized. The results show that as a non-invasive detection method, HTCDGd has huge potential in the aspect of detecting and accurately monitoring hepatic fibrosis change.

The invention discloses a multi-channel in-vivo pharmacokinetic analysis system based on fluorescence monitoring. The multi-channel in-vivo pharmacokinetic analysis system comprises a light source, a multi-path optical switch, a fluorescence spectrometer, a Y-shaped optical fiber probe group, a control circuit, an operation platform, a dual-channel anesthesia machine and an upper computer. According to the invention, multi-channel real-time in-vivo monitoring can be realized, and more accurate biological data relative to in-vitro data can be obtained; optical fiber arrangement is designed according to a slit of the spectrometer, time division multiplexing is performed on the spectrometer by utilizing switching of an optical switch, and simultaneous monitoring of parts such as different tissues, organs and blood vessels of a small animal by six channels is realized; and different physiological pharmacokinetic models are established for analysis according to in-vivo data of a plurality of tissues on an upper computer, so that more accurate data is provided for metabolism of new drugs, and clinical transformation and application of the new drugs are promoted.